Journal
ANNALS OF HEMATOLOGY
Volume 95, Issue 8, Pages 1233-1240Publisher
SPRINGER
DOI: 10.1007/s00277-016-2706-y
Keywords
Wilms' tumor gene 1; Preferentially expressed antigen of melanoma; Minimal residual disease; Myelodysplastic syndromes; Allogeneic hematopoietic stem cell transplantation
Categories
Funding
- Key Program of the National Natural Science Foundation of China [81230013]
- Health Science Promotion Project of Beijing [TG-2015-003]
- Beijing Talents fund [2015000021223ZK39]
- National Natural Science Foundation of China [81400145]
Ask authors/readers for more resources
This study investigated the efficacy of minimal residual disease (MRD) monitoring and MRD-directed preemptive immunotherapy in high-risk myelodysplastic syndrome (MDS) patients who received allogeneic hematopoietic stem cell transplantation (HSCT). MRD assessment consisted of Wilms' tumor gene 1 (WT1) detection with PCR and leukemia-associated immunophenotypic pattern examination with multiparameter flow cytometry (FCM). Post-HSCT, 31 patients were positive for WT1, and 8, for FCM; positivity for WT1 (18.6 vs. 6.1 %, P = 0.040) or FCM (62.5 vs. 3.6 %, P < 0.001) indicated a higher 2-year relapse rate. Twenty-one patients met our combined criteria for MRD, and the presence of MRD was associated with a higher 2-year relapse rate (27.3 vs. 4.5 %, P = 0.003). Preferentially expressed antigen of melanoma (PRAME) expression alone was not an appropriate MRD marker; however, it suggested that the MRD-positive patients may fail to respond to preemptive immunotherapy. In patients positive for both PRAME and MRD, the relapse rate was 60 % despite preemptive immunotherapy. Multivariate analysis confirmed the association between the increased relapse rate and positivity for both PRAME and MRD (hazard ratio = 42.8, P = 0.001). MRD monitoring predicted relapse in high-risk MDS post-HSCT patients, and PRAME- and MRD-positive patients did not benefit from preemptive immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available